Telix Pharmaceuticals Limited has entered into a strategic collaboration agreement with Palo Alto-based Varian Medical Systems, to evaluate the use of advanced prostate cancer imaging within Varian’s radiation treatment planning platform.
Under the terms of the agreement, the parties will leverage Telix’s extensive clinical data for imaging prostate-specific membrane antigen (PSMA) with positron emission tomography (PET) to potentially develop new image-guided treatment planning functions, automated analysis and artificial intelligence capabilities within Varian’s radiation treatment planning technology platforms. The goal of the collaboration is to ensure that the latest standard of care in prostate imaging is able to be an integral part of radiation treatment planning.
Telix CEO Dr Christian Behrenbruch said “Advanced prostate imaging techniques using PET/CT have evolved as a new standard of care for imaging patients across the prostate cancer continuum, from early through to the advanced stages of disease.1 Given that radiation therapy is a mainstay of treatment for patients with prostate cancer, we believe it is vitally important that we work with Varian, the radiation oncology market leader, to ensure all men with prostate cancer are offered radiation therapy for maximum clinical benefit.”
Dr Corey Zankowski, Senior Vice President of Varian’s Oncology Software Solutions said “The additional diagnostic and cancer staging information provided by PSMA PET/CT imaging may offer important insights that impact clinical care decisions for prostate cancer patients. This collaboration with Telix will investigate the potential to incorporate this rich diagnostic information into Varian’s bioinformatics and radiation treatment planning platforms to generate highly personalized and targeted radiation therapy for men with prostate cancer.”
About Prostate Cancer
Prostate cancer is the most common cancer in men, with an estimated 192,000 new cases and 33,000 deaths from prostate cancer in the United States expected in 2020.2 Prostate cancer is more common in older men, with approximately 60% of cases diagnosed in men over 65 years of age. Due to high rates of screening, over 90% of prostate cancers are diagnosed early, when the disease is localised to the prostate or nearby tissues. Both surgery and radiation therapy are effective treatment options for men with localised prostate cancer, offering 5-year survival rates over 95%. More than 60,000 men in the United States undergo radiation therapy for prostate cancer annually,3 with advances in medical imaging and radiation treatment planning continuing to increase the effectiveness and reduce the side effects of radiation therapy.4
1 Trabulsi EJ, et al. Optimum Imaging Strategies for Advanced Prostate Cancer; ASCO Guideline. J Clin Oncol 38: 1963 – 1996 (published online January 15, 2020).
2 American Cancer Society: https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html.
3 Prostate Cancer Foundation: https://www.pcf.org/c/treatment-for-prostate-cancer-external-beam-radiation-therapy/.
4 Garibaldi c, et al. Recent advances in radiation oncology. Ecancermedicalscience. 2017; 11: 85.
Telix, Varian Partner to Improve Advanced Prostate Imaging, Treatment. Appl Rad Oncol.